Replies to post #15673 on GTC Biotherapeutics (fka GTCB)

[go seek]

I agree the ATryn "delay" by LEO is not good for GTC shareholders, especially so, given expectations for P2 results in 1H 09 (results now delayed or worse)

It remains to be seen if LFB can or wants to improve on ATryn sales (GTC says LFB has shown significant interest in ATryn FWIW) Certainly LFB can do no worse than LEO as per commercial sales. Hopefully GTC management can provide more color on expectations once the transition occurs.